BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30717813)

  • 1. The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer.
    Chong GO; Jeong SY; Lee YH; Lee HJ; Lee SW; Han HS; Hong DG; Lee YS
    J Ovarian Res; 2019 Feb; 12(1):12. PubMed ID: 30717813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
    Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
    Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
    Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
    Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
    Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
    Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
    Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
    Gynecol Oncol; 2008 Feb; 108(2):265-70. PubMed ID: 18055006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    González García B; García Vicente AM; Jiménez Londoño GA; Pena Pardo FJ; Bellón Guardia ME; Talavera Rubio MP; Palomar Muñoz A; Gómez Herrero P; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):233-240. PubMed ID: 28284928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
    De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
    Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of 18F-FDG PET/CT-Based Models for Predicting Successful Complete Cytoreduction During Primary Cytoreductive Surgery for Advanced Ovarian cancer.
    Kim J; Gil J; Kim SI; Hwangbo S; Noh JJ; Lee JW; Cheon GJ; Kim JW; Cho YS; Lee M
    Clin Nucl Med; 2023 Feb; 48(2):e51-e59. PubMed ID: 36607373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
    Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings.
    Kim HJ; Choi CH; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
    Taiwan J Obstet Gynecol; 2014 Sep; 53(3):343-7. PubMed ID: 25286788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
    Martoni AA; Fanti S; Zamagni C; Rosati M; De Iaco P; D'Errico Grigioni A; Castellucci P; Quercia S; Musto A; Ricci Maccarini L; Lopci E; Bernardi A
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):81-90. PubMed ID: 21068714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative fluorine 18 fluorodeoxyglucose tumoral uptake ratio between upper and lower abdomen in primary advanced-stage ovarian cancer.
    Shim SH; Kim DY; Seo MJ; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2013 Oct; 23(8):1383-92. PubMed ID: 24257552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Value of
    Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
    Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
    Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
    Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
    J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
    Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
    Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.